2Greenberg P, Cox C, LeBeau MM, et al. international scoring system for evaluating prognosis in myelodysplastic syndromes [ J ]. Blood, 1997,89(6) :2079 -2088.
3Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome [ J ]. Cancer, 2010, 116 (9) :2174 -2179.
4Guillermo GM. Myelodysplastic syndromes:2011 update on diagno- sis, risk-stratification, and management [ J ]. Am J Hemato1,2011,86 (6) :491 -498.
5Takatoku M, Uehiyama T,Okamoto S,et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload oil morbidity/mortality [ J ]. Eur J Haemato1.2007.78 (6) :487 - 494.
6Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron o- verload and transfusion dependency on survival and leukemic evolu- tion in patients with myelodyspl.astic syndrome [ J ]. Blood, 2008, 112:640.
7Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology:myelodysplastic syndromes[ J]. J Natl Corn-pr Cane Netw,2011,9(1) :30 -56.
9Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes:Results of six cross- sectional physician surveys [ J]. J Natl Cancer Inst, 2008, 100 (21) :1542 - 1551.
10Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating a- gents in the treatment of anemia in myelodysplastic syndromes : A meta-analysis [ J ]. Ann Hemato1,2008,87 (7) :527 - 536.
